Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab
Crossref DOI link: https://doi.org/10.1007/s00259-017-3870-6
Published Online: 2017-11-10
Published Print: 2018-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Anwar, Hoda http://orcid.org/0000-0002-4071-5217
Sachpekidis, Christos
Winkler, Julia
Kopp-Schneider, Annette
Haberkorn, Uwe
Hassel, Jessica C.
Dimitrakopoulou-Strauss, Antonia
Funding for this research was provided by:
Deutsche Krebshilfe
License valid from 2017-11-10